Systemic Therapy in Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) and Ki Index 5-10%

#1026

Introduction: Phase III trials of sunitinib, everolimus and octreotide lar confirmed that these drugs improved progression-free survival (PFS) in well-differentiated PNET, low/intermediate grade pNET and well-differentiated midgut NETs, respectively. CLARINET is the 1st phase III study that showed PFS benefit of SSA, lanreotide, in both P- and midgut NET and in Ki-67 5-10%.

Aim(s): To assess the systemic treatment of Ki-67 5-10% metastatic GEP-NET.

Materials and methods: Two-hundred and seventeen pts with metastatic GEPNET were attended in a Spanish Medical Oncology Department from 2005-2012. Twenty of these 217 (9%) which had Ki-67 5-10% GEPNET were analysed.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Jiménez-Fonseca P, Carmona A, Faez L, Solis P, Rodriguez D,

Keywords: Ki-67, pancreatic neuroendocrine tumor, systemic therapy,